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Abstract: The expression of basal cytokeratin markers CK5/6 in breast carcinomas has been associated with high histological grade 
and poor clinical outcome. A previous study has shown that CK5/6 can be detected in up to 17% of invasive lobular carcinomas (ILC). 
Here we study the expression of three basal cytokeratin markers (CK5/6, CK14, and CK17) in 53 ILC cases diagnosed by histology 
and lack of E-cadherin expression. Among them, 42 were classic lobular carcinomas, 6 were tubular-lobular carcinoma, and 5 were 
pleomorphic lobular carcinomas. There was no significant difference among these three groups in patients’ age, tumor size, uni- and 
multi-focality, expression of ER and PR, lymphovascular invasion, perineural invasion and lymph node metastasis. The only statisti-
cally different factor was HER2 over-expression, which was observed only in pleomorphic ILC (P = 0.0073). None of the 53 cases 
expressed CK5/6, CK14 or CK17; and 51/53 cases expressed luminal markers CK8 and CK18, and the two negative cases were both 
classic lobular   carcinoma, with positivity for ER and PR. In conclusion, all 53 cases of ILC failed to show expression by any of the three 
basal CK markers, suggesting that very few ILC will demonstrate a basal phenotype when assessed by immunohistochemistry (IHC). 
More studies are needed to investigate molecular classification in lobular carcinoma of the breast.
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Introduction
Infiltrating  lobular  carcinoma  (ILC)  is  the  second 
most common histologic type of breast cancer and 
comprises  5%–15%  of  newly  diagnosed  invasive 
tumors.1,2 Its incidence has been increasing over the 
last 20 years, mainly in women over 50 years of age. 
Recent studies showed that ILC carried distinct bio-
logic  and  prognostic  factors  when  compared  with 
infiltrating  ductal  carcinoma  (IDC).  With  a  large 
database of over 50,000 patients and a median fol-
low-up of 87 months, Arpino et al2 found that ILC is 
significantly more likely to occur in older patients, 
more likely to be larger in size, and to be ER and PR 
positive and HER2 negative when compared to IDC. 
Contralateral involvement is more common with ILC; 
however, the 5 year disease-free survival and overall 
survival are comparable with IDC. More recently, a 
multi-institutional study with over 2000 patients and a 
median follow-up of 13 years has confirmed the above 
findings, and pointed out that ILC had a significantly 
better (P , 0.01) disease-free survival and overall 
survival early in the clinical course compared with 
IDC.   However, this better prognosis was time depen-
dent with a significant trend toward late recurrence 
with ILC compared to IDC (P , 0.01).3 Rakha et al4 
showed that ILC has an indolent but progressive clin-
ical course with nearly linear survival curves which 
cross those of IDC after approximately 10 years of fol-
low up, thus eventually exhibiting a worse long-term 
outcome. Interestingly, Viale et al recently5 reported 
a single institution study with matched “classic” ILC 
and IDC for year of surgery, age, menopausal status, 
tumor size, nodal involvement, hormone receptor sta-
tus and histological grade. In this study, there was no 
difference between these two groups in disease-free 
or over-all survival, or in locoregional relapse to time 
of distant metastasis. A study with over 500 cases by 
Orvieto et al6 have shown that tumor size, lymph node 
metastasis and hormone status are the most significant 
prognostic markers for ILC; and “classical” ILC was 
associated with lower axillary node metastasis and 
breast-related events, and better disease-free survival 
and overall survival compared to its variants includ-
ing alveolar, solid, pleomorphic subtypes, etc. ILC 
cases show a distinct pattern for metastatic dissemi-
nation to peculiar anatomic sites, such as the gastro-
intestinal tract and serosal surface.2 ILC is   associated 
with an increased incidence of bone metastasis but a 
decrease in regional and lung   metastasis.3 ILC patients 
show a better response to adjuvant hormonal therapy 
with improvement in survival when compared with 
matched patients having IDC,4 but they are less likely 
to have a complete pathologic response to neoadju-
vant chemotherapy.7,8
The hallmark of the molecular features of lobu-
lar  carcinoma  is  the  loss  or  down-regulation  of 
  E-cadherin compared to ductal lesions.9–11 E-cadherin 
is a calcium-dependent transmembrane protein that 
plays a functional role in cellular adhesion and binds 
to the actin cytoskeleton through interactions with 
β and α- catenin.12–14 Genetic studies have demon-
strated that ILC and IDC will show distinctive molec-
ular features,15,16 with different levels of expression of 
many genes involved in cell adhesion, motility, apop-
tosis, protein folding, extracellular matrix and protein 
phosphorylation.17 Weigelt B et al18 recently showed 
that 5.8% of the transcriptionally regulated genes are 
significantly  differentially  expressed  in  ILC  com-
pared to grade- and molecular subtype-matched IDC; 
while only 0.1% of genes show differential expression 
between classic ILC and pleomorphic ILC, support-
ing again that ILC and IDC are   genetically distinct 
entities.
Recent studies on molecular classification of the 
breast carcinomas have shown that basal subtype has 
a worse prognosis when compared to luminal sub-
type, and one of the IHC markers for basal subtype 
is  CK5/6.  One  previous  study  has  shown  that  the 
basal marker CK5/6 can be detected in up to 17% of 
ILC.19 Here we study the expression of three basal 
cytokeratin markers in 53 cases of histologically and 
  E-cadherin confirmed ILC.
Methods
Fifty-three cases of ILC between 2000 and 2005 were 
identified from the files of the Department of Pathol-
ogy and confirmed by two pathologists (NK, PT). The 
expression of E-cadherin was also analyzed by immu-
nohistochemistry (IHC) and showed that none of the 
cases in this study expressed it, including both the 
tubular and lobular component of the tubular-  lobular 
carcinoma.  Clinical  and  pathological  information 
including the patients’ age, tumor size, multifocality, 
ER, PR and HER2 status, lymphovascular invasion, iLC do not express basal cytokeratins
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perineural invasion, and status of lymph nodes were 
reviewed  and  recorded.  One    representative  section 
from each case was also stained with antibodies to 
basal markers CK5/6 (clone D5/16B4, Dako), CK14 
(clone LL002 Noracastra) and CK17 (clone E3, Dako), 
and luminal markers CK8 (clone 35bH11, Dako) and 
CK18 (clone DC10, Dako). ER (clone ID5, Dako) 
and PR (clone PgR636, Dako) were scored using the 
Allred scoring system with less than or equal to 2 
as negative, and a score of 3 or greater as positive.20 
HER2   (Herceptest, Dako) was scored according to the 
new CAP/ASCO guidelines.21 CK5/6, CK14, CK17, 
CK8  and  CK18  were  scored  as  positive  with  any 
strong cytoplasmic/membrane staining. An antibody 
panel for breast cancer classification based on IHC 
analysis of four markers described by Nelson et al22 
was used in this study. Briefly, Liminal A subtype 
was defined as ER and PR positive, HER2 negative, 
CK5 and EGFR positive or negative; Luminal B sub-
type as ER and PR positive, HER2 positive, CK5 and 
EGFR positive or negative; HER2 over-expression 
subtype as ER and PR negative, HER2 positive, CK5 
and EGFR positive or negative; and Basal subtype 
as ER and PR negative, HER2 negative, CK5 and/or 
EGFR positive.
For the statistical analysis, the means of age and 
size of tumors of specific types of ILC were given, 
and the differences between types of ILC were tested 
by  using  t-test.  Software  SAS  9.1.3  was  used  to 
perform Fisher’s exact test to detect the difference 
between classic ILC, tubular-lobular carcinoma and 
pleomorphic ILC.
Results
Among the 53 cases of ILC, 42 were classic lobular 
carcinomas, 6 were tubular-lobular carcinomas, and 
5 were pleomorphic lobular carcinomas. There was 
no significant difference among these three groups 
in  patients’  age,  tumor  size,  uni-  or  multifocality, 
expression of ER and PR, lymphovascular invasion, 
perineural invasion and lymph node metastasis. The 
only  statistically  different  factor  was  HER2  over-
expression,  which  was  only  observed  in  the  pleo-
morphic invasive lobular carcinomas (P = 0.0073) 
(Table 1; Figure 1). None of the 53 cases was positive 
for basal cytokeratin markers CK5/6, CK14 or CK17. 
All but two cases expressed CK8 and CK18, and the 
two negative cases were both classic lobular carci-
nomas and positive for both ER and PR (Table 2). 
Interestingly, both luminal cytokeratin markers (CK8 
and CK18) were uniformly positive or negative in 
every case. Using the antibody panel for breast can-
cer classification, ILC in our study could be classi-
fied as Luminal A subtype for 100% of the classic 
lobular and tubular-lobular carcinomas and 60% of 
the pleomorphic lobular carcinomas; the other 40% 
were classified as Luminal B subtype due to the over-
expression of HER2 (Table 3).
Discussion
Invasive ‘breast cancer’ represents a heterogeneous 
group of distinct entities that vary widely in terms of 
their morphologic spectrum, tumor biology, clinical 
presentation and behavior. Roughly 25% of invasive 
breast tumors can be recognized as ‘special histologic 
Table 1. Clinical and Pathological features in each histologic subtype of invasive lobular carcinomas.
Types of ILc P value
classic ILc Tubular-lobular pLc
Case number 42 6 5
Clinical-pathological
Age (mean, years) 58.4 58.8 55 0.8386
Size (cm) 2.56 3.43 7.8 0.8067
Multifocal 6 (14%) 2 (33%) 1 (20%) 0.3325
eR+ 41 (98%) 6 (100%) 5 (100%) 1.0000
PR+ 35 (83%) 5 (83%) 5 (100%) 1.0000
heR2+ 0 (0%) 0 (0%) 2 (40%) 0.0073
LVi 7 (17%) 2 (33%) 1 (20%) 0.5669
Pni 2 (5%) 1 (17%) 0 (0%) 0.5099
Ln 9/33 (27%) 2/6 (33%) 3/4 (75%) 0.2333Khilko et al
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types’  based  on  distinctive  cytologic  features  and 
growth patterns. While these ‘special type’ tumors 
have  demonstrated  considerable  prognostic  signifi-
cance in clinical studies, little attention has been paid 
to  the  molecular  genetic  basis  for  these  histologic 
entities in recent attempts at molecular classification 
of breast cancer, which have been derived primar-
ily from the study of invasive ductal carcinoma of 
no specific type (IDC NOS). The integration of the 
histologic special types of breast cancer into current 
molecular classification schemes may have important 
prognostic  and  predictive  implications  for    clinical 
management.  It  is  also  unclear  at  present  whether 
prognostic gene sets, including the 70-gene prognosis 
profile23 and 21-gene recurrence score24 have similar 
prognostic power when applied to the special types of 
breast cancer. Weigelt et al18,25 demonstrated that clas-
sic ILC and tubular carcinomas showed   similarities at 
the level of gene expression and immunohistochemi-
cal profiles, falling into a luminal subtype, with low 
levels of e-cadherin expression distinguishing ILC. 
Such  tumors  would  be  expected  to  demonstrate 
expression of ER and to have a more indolent clinical 
course of disease.
Initial  evidence  for  molecular  subtypes  of 
breast carcinomas came from a cDNA-microarray 
study  of  gene  expression,  which  divided  tumors 
ABCD
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Figure 1. examples of the staining patterns of each subtype of iLC. A–D) Classic iLC for he, heR2, CK5/6 and CK8; e–H) Tubular-lobular iLC for he, 
heR2, CK5/6 and CK8; I–L) Pleomorphic iLC for he, heR2, CK5/6 and CK8.
Table 2. expression of CK5, CK8, CK18, CK14 and CK17 
in each histologic subtype of invasive lobular carcinomas.
Types of ILc P value
classic 
ILc
Tubular-
lobular
pLc
Case number 42 6 5
CK expression 1.0000
CK5 0% 0% 0%
CK8 95% 100% 100%
CK18 95% 100% 100%
CK14 0% 0% 0%
CK17 0% 0% 0%
Table  3.  Molecular  classification  for  each  histologic 
  subtype of invasive lobular carcinomas.
Types of ILc
classic ILc Tubular-lobular pLc
Case number 42 6 5
Luminal A 100% 100% 60%
Luminal B 0% 0% 40%
heR2 0% 0% 0%
Basal 0% 0% 0%iLC do not express basal cytokeratins
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into    basal-like,  luminal  A,  luminal  B,  HER2 
  over-expression, and normal breast-like subgroups, 
each with distinct clinical outcomes.26–28 In an effort 
to develop a similar classification that is clinically 
significant,  technically  simple,  reproducible  and 
readily  available,  several  IHC-based  molecular 
classifications for breast cancer have been investi-
gated  extensively.  These  include:  1)  Cytokeratin-
based classification divides breast   carcinomas into 
basal subtype (CK5/6, CK14, CK17 positive), and 
luminal  subtype  (CK8,  CK18  positive  and  basal 
negative);29–33 2) ER, PR and HER2-based classi-
fication defines the basal subtype as an absence of 
expression of ER, PR and HER2;34–38 3) ER, HER2, 
EGFR  and  CK5/6-based  classification22,39  defines 
the basal subtype as ER and HER2 negative, and 
CK5/6 and/or EGFR positive, with 76% sensitiv-
ity and 100% specificity, respectively, compared to 
basal subtype defined by gene expression profiling. 
Although these IHC-based molecular classifications 
all show basal subtype has the worse prognosis, they 
are not interchangeable.40 In addition to various defi-
nitions with similar terminology for molecular clas-
sification, other limitations for IHC-based molecular 
classifications include differences in patient cohorts, 
tumor grades, antibody methodology, and definition 
of positive staining for each marker.
Fadare et al19 used one basal marker (CK5/6) to 
study 82 cases of invasive lobular carcinoma, and 
observed that 17% of the cases expressed CK5/6. In 
contrast, we did not identify any expression in any 
of our cases by any of the three basal cytokeratin 
markers (CK5/6, CK14 and CK17). In Fadare et al’s 
study, CK5/6 was considered as immunologically 
reactive if there was cytoplasmic staining unequivo-
cally above the background, similar to our defini-
tion of positive staining for any CK marker. 8/14 of 
their cases showed strong diffuse and intense stain, 
while the other 6 remaining cases showed patchy 
and intense stain. Our study used the same mono-
clonal antibody for CK5/6 as was used by Fadare 
et al purchased from the same vendor. Our experi-
ence of IHC analysis on CK5/6, CK14 and CK17 
positive cases of IDC has been that most cases pres-
ent with strong patchy stains while only a few cases 
present with strong and diffuse stain. The reason 
for  the  different  observation  could  be  due  to  the 
  number of  pre-analytical variables between our two 
  laboratories. Another less likely possibility would be 
due to differences in the patient population included 
in these two studies.
About 20 years ago, Eusebi et al41 showed that 
PLC is a more aggressive tumor with apocrine dif-
ferentiation. Since then many studies have focused on 
this more aggressive subtype of ILC. Buchanan et al42 
have  found  that  pleomorphic  lobular  carcinomas 
are larger tumors, have more positive nodes, more 
  frequently develop metastatic disease, and more often 
require mastectomies. By gene expression profiling, 
classic  ILC  falls  into  the  luminal  subtype,25  while 
PLC may be of luminal, HER2 or molecular apocrine 
subtype by expression profiling, although PLC seems 
to share a common molecular genetic pathway with 
classic  lobular  carcinomas.43–45 Although  histologic 
subtype was not- mentioned in the report by Fadare 
et  al19  they  did  mention  the  correlation  between 
CK5/6 expression and ER negativity, high histologic 
grade, and high mitotic index, suggesting some of 
their cases were likely to be pleomorphic ILC. There 
are 5 pleomorphic lobular carcinomas in our study, 
and none of them expressed any of the three basal 
CK markers. Pleomorphic ILC consists of 9.4% of all 
lobular carcinomas in our study, comparable with a 
rate of 10.8% observed by Buchanan et al42 in a much 
larger study; 2 of them (40%) over-express HER2, 
compatible with a prior study by Frolit et al46 who 
found 53% of PLC over-expressed HER2.
In summary, although one prior study suggested 
that a significant portion of invasive lobular carcino-
mas express basal cytokeratin markers,19 our study 
with three commonly used basal cytokeratin mark-
ers failed to confirm their findings. It is very possible 
that we have not studied enough cases to make a con-
clusion, but it is unlikely that the level of basal CK 
marker expression would reach 17%. More studies 
are needed to investigate the molecular classification 
in lobular lesions.
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